Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Benazepril Hydrochloride" patented technology

The hydrochloride salt of benazepril, a carboxyl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, benazepril is metabolized to its active form benazeprilat. Benazeprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II, resulting in vasodilation. Benazeprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.

Amlodipine benazepril impulse tablet and preparation method thereof

The invention discloses an amlodipine benazepril impulse tablet and a preparation method thereof. The amlodipine benazepril impulse tablet comprises a rapid-release tablet core and a controlled-release coating layer, wherein the rapid-release tablet core is prepared from a main drug and a tablet core auxiliary material, and the main drug is prepared from amlodipine besylate and benazepril hydrochloride. The preparation method comprises the following steps that (1) after the main drug and the tablet core auxiliary material are uniformly mixed, the rapid-release tablet core is prepared by adopting a direct powder compression method; (2) optionally, a swelling coating layer is formed on the rapid-release tablet core prepared in the step (1); and (3), the controlled-release coating layer is formed on the rapid-release tablet core prepared in the step (1) or the swelling coating layer prepared in the step (2) so as to obtain the amlodipine benazepril impulse tablet. According to the amlodipine benazepril impulse tablet and the preparation method thereof, the drug release time lag of the amlodipine benazepril impulse tablet can reach 1-10 h, the drug is completely and rapidly released, the drug release time lag accords with the pathogenetic time rule of hypertension and adverse reaction thereof, and the compliance of a patient is better; and in addition, a preparation process is simple, and relatively good industrial application values are achieved.
Owner:SHANGHAI SUNTECH PHARMA

Compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof

The invention discloses a compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof, wherein preparation containing benidipine hydrochloride and benazepril hydrochloride serve as effective components of the medicament. According to the compound preparation, the defects of large dose and high side effect of single drug are overcome, and the compound preparation disclosed by the invention is obtained by compounding the benidipine hydrochloride and benazepril hydrochloride. Oral preparations with different forms can be prepared by the preparation, due to synergic and complementary effects of medicaments, the compound preparation has reinforced treatment effect, the medicament dose is reduced in clinical application, adverse reaction of a patient is lightened, and the compound preparation can be accepted easily. The compound preparation has remarkable treatment effect in mild and severe hypertension, and is suitable for hypertension patient with cardiovascular remodeling, and patients with renal hypertension, hypertension with renal damage or with diabetic renal damage. Furthermore, the compound preparation has low price, simple preparation and easy popularization and application.
Owner:济南龙华医药技术有限公司

Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof

ActiveCN103316101BReduce contentImprove lipid metabolism disorder in the bodyMetabolism disorderUrinary disorderCoptisTubulointerstitial fibrosis
The invention provides a traditional Chinese medicine for treating diabetic nephropathy and a preparation method thereof. The traditional Chinese medicine for treating diabetic nephropathy is prepared from the following traditional Chinese medicinal materials by weight: 6 to 15 parts of common fenugreek seed, 6 to 15 parts of milkvetch root, 3 to 8 parts of epimedium herb, 3 to 8 parts of malaytea scurfpea fruit, 3 to 8 parts of Asiatic cornelian cherry fruit, 1 to 5 parts of rhubarb root and rhizome, 3 to 8 parts of Chinese cassia tree and 2 to 6 parts of coptis. The invention further discloses the preparation method for the traditional Chinese medicine. According to the invention, renal tubulointerstitial fibrosis is dose-dependently inhibited through reduction of urine protein of rats with diabetic nephropathy, so a certain treatment effect is exerted on type 1 diabetic nephropathy and the treatment effect is equal to that of a benazepril hydrochloride tablet but better than that of a kidney-qi-tonifying pill. The traditional Chinese medicine also exerts a certain treatment effect on rats with type 2 diabetic nephropathy through approaches like protection of a kidney structure, reduction of the content of urine protein and improvement of in-vivo lipid metabolism disorder.
Owner:WUHAN JIANHENG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products